Guidelines & Consensus
Rezvilutamide in Metastatic Hormone-Sensitive Prostate Cancer
Mi et alBJU International
An analysis published in BJU International addresses the clinical utility of rezvilutamide in patients with metastatic hormone-sensitive prostate cancer. The report focuses on the interpretation of evidence from the CHART trial and reviews how these findings inform the clinical applicability and therapeutic positioning of rezvilutamide within current European Association of Urology guidelines.
Key Takeaways
- CHART trial evidence supports the clinical applicability of rezvilutamide for metastatic hormone-sensitive prostate cancer within European Association of Urology guidelines.
Read the original sourceBJU International
